Author:
Crombet Ramos Tania,Morera Díaz Yanelys,Neninger Vinageras Elia,Santos Morales Orestes,Saavedra Hernández Danay,Bequet Romero Mónica,Sánchez Ramírez Javier,Lage Dávila Agustin
Publisher
Springer International Publishing
Reference63 articles.
1. Aalberse RC, Stapel SO, Schuurman J, Rispens T (2009) Immunoglobulin G4: an odd antibody. Clin Exp Allergy 39(4):469–477
2. Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, Cairnduff F, Selby PJ, Perren TJ, Lansdown M, Banks RE (2000) Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 60(11):2898–2905
3. Baselga J (2001) The EGFR as a target for anticancer therapy–focus on cetuximab. Eur J Cancer 37(Suppl 4):S16–S22
4. Baselga J (2003) A review of EGFR targeted therapy. Clin Adv Hematol Oncol 1(4):218–219
5. Berthelet E, Pickles T, Lee KW, Liu M, Truong PT, Prostate Cancer Outcomes Initiative (2005) Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/mL. Int J Radiat Oncol Biol Phys 63(3):781–787